Why Does Beta-Amyloid Build Up in the Brain—And Is It Reversible?
We’ll get to the important question of beta-amyloid plaque build-up, but first, the basics: What is beta-amyloid protein, what does beta-amyloid do in the…
We’ll get to the important question of beta-amyloid plaque build-up, but first, the basics: What is beta-amyloid protein, what does beta-amyloid do in the…
How does Alzheimer’s affect the brain? Here’s a look at what parts of the brain Alzheimer’s affects and how the disease progresses. Lapses in…
Donald Weaver, a researcher and physician who acts as co-director at the Krembil Brain Institute, provides evidence that Alzheimer’s is a result of the…
A new study reveals that Asian, Black, and Hispanic patients are less likely to develop beta-amyloid plaques — a key Alzheimer’s biomarker — alongside…
Here’s a theory: Alzheimer’s biomarker beta-amyloid could — rather than killing the brain — actually be trying to defend it. The provocative idea builds on…
A protein called HDAC I is important for folding and storing DNA inside of cells. Scientists found low levels of this protein in Alzheimer’s…
Her brain had all the signs of Alzheimer’s. She never got it. What can she teach us? Scientists examine the curious case of a…
Bombshell exposé in Science magazine and follow-up reporting “make a mountain out of a molehill,” leading Alzheimer’s experts say. The media is reporting that…
Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
The FDA’s approval of Biogen’s new anti-amyloid drug Aduhelm was a landmark moment for Alzheimer’s — and it comes with no small amount of…
“Historic moment:” Today, the FDA gave Biogen’s investigational Alzheimer’s drug aducanumab its approval, with the requirement that they conduct a post-approval trial. In a…
We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…
If aducanumab — an experimental treatment that may slow the progression of Alzheimer’s — gets FDA approval, how will the healthcare system meet the anticipated…
“Can I look into your future and can I accurately estimate how much beta-amyloid you’re going to accumulate over the next two years, the…
While some scientists are focused on targeting beta-amyloid plaques to treat Alzheimer’s, others are honing in on another hallmark of the disease — pathological…